Newsfeed : iPrEx Study Shows PrEP Reduces HIV Risk

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Newsfeed » November 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 23, 2010

iPrEx Study Shows PrEP Reduces HIV Risk

A new study called iPrEx shows that people at high risk for HIV—men who have sex with men and transgender women who have sex with men—who took a single daily pill containing two HIV medications (emtricitabine and tenofovir) had an average of almost a 44 percent reduction in HIV risk, according to a statement from Gladstone Institutes, the nonprofit group that coordinated the study published in The New England Journal of Medicine (NEJM). The study included 2,499 participants in six countries. It is the first study to show that pre-exposure prophylaxis (PrEP) reduces HIV risk in people.

Throughout the study, participants received HIV prevention services to lower their HIV risk, including condoms, safer-sex counseling, treatments for sexually transmitted infections and HIV testing. Half of the participants received the PrEP pill, and the other half a placebo. On average, the PrEP pill reduced HIV risk by 43.8 percent. Participants who used the PrEP pill 50 percent or more of the days reduced their HIV risk by 50.2 percent. Participants who used the PrEP pill 90 percent or more of the days reduced their HIV risk by 72.8 percent. (In all, 36 people on the PrEP pill contracted HIV compared with 64 people on the placebo.) Health officials will review the study to determine whether and how to recommend PrEP.

To read the NEJM article, click here.

To read the Gladstone Institutes statement, click here.

Search: iPrEx, PrEP, pre-exposure prophylaxis, emtricitabine, tenofovir, The New England Journal of Medicine, NEJM, Gladstone Institutes


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 2 (of 2 total)    

Frederick Wright, Tampa, 2010-12-02 11:54:56
If you look at the price in bulk tier genric cost, if PEDFAR would disclose, then one might see that the bulk price in the Charity Funding by PEDFAR or The Pooling fund set up by President Clinton; these pills might be costing 300 dollars a year, with bulk genric pricing for a penny a pill made by India or Generic/wink, then you might see the plan of low cost global prevention and less global new HIV cases, hence less chance of other (TB etc) global infections coming over the ocean to the USA

scott alan, laguna beach, 2010-11-30 12:30:08
i amazes me that people would spend $900+ a month for this medication when condoms are much cheaper with NO SIDE EFFECTS!

comments 1 - 2 (of 2 total)    


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.